Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

Table 2 Confirmed objective responses

Response	1 L (n = 62)	2 L (n = 20)
Best overall response, n (%)
Complete response	1 (1.6)	0
Partial response	9 (14.5)	2 (10.0)
Stable disease	38 (61.3)	13 (65.0)
Progressive disease	11 (17.7)	4 (20.0)
Not evaluable	3 (4.8)^a	1 (5.0)^b
Objective response rate (95% CI), %	16.1 (8.0–27.7)	10.0 (1.2–31.7)
Disease control rate, %	77.4	75.0
Response duration	1 L (n = 10)	2 L (n = 2)
Median duration of response (95% CI), months	9.9 (2.8–NE)	NE (6.9–NE)
Proportion of patients with specified duration of response (95% CI), %^c
6 months	60.0 (25.3–82.7)	100.0 (NE)
12 months	30.0 (7.1–57.8)	50.0 (0.6–91.0)

^a Due to no postbaseline assessment (n = 2) or stable disease of insufficient duration (< 6 weeks after start date without further tumor assessment; n = 1)
^b All postbaseline assessments not evaluable (n = 1)
^c Based on Kaplan-Meier estimates
1 L first-line subgroup, 2 L second-line subgroup, CI confidence interval, NE not evaluable